Ki Young Sohn, CEO of Enzychem Lifesciences, recognized by the World Biz Magazine Leadership Awards with the “Top 100 Innovation CEO” award


Content of the article


Advertisement 2

Content of the article

LONDON, May 11, 2022 (GLOBE NEWSWIRE) — Ki Young Sohn is Chairman and CEO of Enzychem Lifesciences, a development-stage biotechnology company. With over 30 years of experience in the life sciences and finance industry, Ki Young previously successfully led teams in various pharmaceutical settings. Most recently, he led positive Phase 2 results in the US for Enzychem Lifesciences’ lead candidate EC-18 in chemoradiation-induced oral mucositis (CRIOM) and execution of the partnership with Zydus Cadila to manufacture and distribute the world’s first pDNA COVID-19 vaccine. .

Founded in 1999, Enzychem Lifesciences develops novel small molecule therapies to target fundamental pathways of inflammation, for patients with unmet needs. Based on more than two decades of research, Enzychem has developed its lead candidate EC-18, an oral small molecule derived from Sika deer antler, which has been shown to be active in a number of different indications.

Advertisement 3

Content of the article

In recognition of Ki Young Sohn’s invaluable contributions to the biopharmaceutical industry and Enzychem Lifesciences’ focus on improving the lives of patients with cancer and inflammatory diseases, World Biz Magazine awarded Mr. Sohn a place in the Top 30 of the global list of 100 distinguished honorees.

Ki Young Sohn was also interviewed in World Biz magazine where he shared his thoughts on Enzychem Lifesciences’ mission and the factors that contributed to the company’s rapid growth. Read the interview here.

“It is a great honor to receive the “Top 100 Innovation CEO” award from World Biz Magazine. Developing new therapies for patients with unmet needs is central to Enzychem’s mission and culture. We will continue to innovate and advance the development of our therapies for patients,” said Ki Young Sohn, President and CEO of Enzychem Lifesciences.

Advertisement 4

Content of the article

World Biz Magazine’s Top 100 Innovation CEO Awards recognize business leaders around the world who are making major strides in their industries. It recognizes product, service, functional, strategic and managerial innovation. It also recognizes individuals who demonstrate exceptional business acumen and market integrity. Sustainability is a cornerstone of the awards and is an integral part of the selection criteria. Each year, more than 40,000 leaders are shortlisted and after a rigorous evaluation process, only 100 winners are selected.

Mike Walters, Editor of World Biz Magazine: “We are delighted to announce that Ki Young Sohn is the recipient of the award. Being highlighted in the Top 30 of 100 Winners is a testament to the pivotal role of Enzychem Lifesciences under the leadership of Ki Young Sohn in focusing on patients with high unmet needs in oncology, severe inflammatory and respiratory diseases. Along with its innovation DNA and exciting growth, Enzychem Lifesciences is an ESG-focused company, best exemplified by its commitment to making COVID-19 vaccination available in low-to-middle income countries in Latin America and Asia.

Advertisement 5

Content of the article

World Biz Magazine is the leading global C-Suite business journal with a readership spanning 32 countries, WBM focuses on leadership, innovation, investment and social responsibility.

Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases. EC-18 acts as an immunomodulator, facilitating resolution of inflammation and early return to homeostasis. Enzychem is headquartered in South Korea, with an office in the United States.

Press contact: John West,

Related images


This content was published via the press release distribution service.




Postmedia is committed to maintaining a lively yet civil discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to be moderated before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread you follow, or if a user follows you comments. Visit our Community Rules for more information and details on how to adjust your E-mail settings.


Comments are closed.